With an MHRA-approved GMP (Good Manufacturing Practice) compliant Clinical Manufacturing Facility outside Glasgow, TC Biopharm is commercialising unique biological properties exhibited by gamma delta T cells .

TC BioPharm has developed ImmuniCell®, an autologous therapy which involves cleanroom-based expansion of the cells over a 2 week period to formulate a treatment for a wide-variety of different tumour types and viral infections. The manufacturing process comprises several steps – isolation of peripheral blood mononuclear cells, selection/activation of gamma delta T cells and culture expansion in a GMP environment, providing therapeutically relevant cell numbers prior to administration.

Present as a small sub-population of circulating lymphocytes, gamma delta T cells recognise and target specific structures present on the surface of cancerous cells, and cells that have been virally infected. On recognising these cell-surface components, gamma delta T cells kill their target by injecting a potent toxin (granzyme) which induces cell death (apoptosis).

ImmuniCell®

ImmuniCell® is TCB’s lead product currently going through an adaptive phase II/III in clinical trial approved by MHRA UK. The clinical trial of ImmuniCell® treatment for patients with Melanoma (skin), Non-Small Cell Lung Carcinoma (NSCLC) (lung) and Renal Cell Carcinoma (RCC) (kidney) is an adaptive, open label trial and is designed to identify an optimal, safe dose for future clinical trials, to identify a response signal from at least one of the cancers under investigation as well as to confirm safety and efficacy.

Learn more

Discovery
Pre-Clinical
Clinical Trials
In Market

ImmuniCAR®

Chimeric Antigen Receptors (CAR) are genetically engineered molecules specifically designed to redirect immune cells, typically αβ T lymphocytes, against antigens expressed on the surface of tumour cells. The CAR is designed in a modular fashion, and comprises an extracellular antigen binding domain (usually part of an antibody), a spacer region that links it to the transmembrane region and an intracellular signalling domain that transmits an activation signal to the cell upon antigen recognition. Identification of an antigen by a CAR engineered T cell results in its activation, proliferation and will initiate signals to attack and destroy the cancer cells.

Learn more

Discovery
Pre-Clinical
Clinical Trials
In Market

OmnImmune®

OmnImmune® is a second generation Gamma delta T cell therapy developed by TCB aiming to expand the therapeutic potential of ImmuniCell®. OmnImmune® is an allogeneic product, which means that the Gamma delta T cells are derived from healthy donors rather than the patients themselves. OmnImmune® can be produced and banked in advance ready for use as an off-the-shelf cell therapy product for the treatment of a wide range of cancers, viral and bacterial infections. Gamma delta T cells will be derived from healthy donors and exponentially expanded in cell cultures to produce a product, which can be shipped to multiple clinical sites and effectively treat numerous disease indications.

Learn more

Discovery
Pre-Clinical
Clinical Trials
In Market

OmniStem®

TCB is developing OmniStem®, a proprietary universal stem cell treatment suitable for clinical applications. OmniStem® is characterised by:

  • Minimal risk for development of GVHD
  • No limitation of source availability
  • Pluripotent characteristics but no tumorigenicity

Learn more

Discovery
Pre-Clinical
Clinical Trials
In Market